Germany And Netherlands Medical Marijuana Market Size, Share & Trends Analysis Report By Product (Flower, Oil), By Application (Chronic Pain, Mental Disorder, Cancer), By Country, And Segment Forecasts, 2025 - 2030

October 2024 | 80 pages | ID: G65AE33A48B7EN
Grand View Research, Inc.

Abstracts

This report can be delivered to the clients within 2 Business Days

Germany And Netherlands Medical Marijuana Market Growth & Trends

The Germany and Netherlands medical marijuana market size is expected treach USD 299.4 million in 2030 and is projected tgrow at a CAGR of 25.3% from 2025 t2030. The growing adoption of marijuana for the treatment of chronic diseases is positively impacting the growth. Furthermore, increasing its legalization and use for therapeutic purposes is further bolstering revenue growth over the forecast period.

Based on the product, the flower segment dominated the market in 2019. Flowers are generally utilized for smoking purposes and have applications in a variety of health-related conditions such as in the treatment of glaucoma and nausea. Such factors are contributing tthe increase in demand for the flower. In addition, rapid onset of action with respect tthe smoking of flowers and its applications in alleviating chronic pain, reducing cancer, stopping the progression of Alzheimer’s disease is further propelling the market growth.

In 2019, the chronic pain segment accounted for the highest revenue share. This growth is attributed tthe presence of legal programs in both the countries and its increasing acceptance for various chronic conditions. In addition, scientific literature supporting its benefits in the treatment of various diseases, including chronic pain is further fueling the growth.

Germany dominated the market with a revenue share of 98.0% in 2019 owing tthe increasing population and high demand for medical use. Furthermore, liberal government regulations, sanctioning of cultivation licenses in the country, and its legalization for health-related or therapeutic purposes are boosting the growth of the market in the country.

Germany And Netherlands Medical Marijuana Market Report Highlights

• Increasing adoption of marijuana for the treatment of chronic diseases and its legalization tbe used for therapeutic purposes is driving the market
• Oil products dominated the market and accounted for the largest revenue share of 55.3% in 2024. This growth is attributed testablished clear regulations by both countries that facilitate the production and distribution of cannabis oil, making it more accessible tpatients.
• The chronic pain segment dominated the market in 2024, owing tthe presence of legal programs in both the countries and increasing acceptance of medical marijuana ttreat various chronic conditions.
• The Netherlands medical marijuana market dominated the market and accounted for the largest revenue share of 91.2% in 2024. This growth is attributed tits long-standing history of cannabis use and progressive regulatory framework.

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

1.1. Market Segmentation & Scope
1.2. Segment Definitions
  1.2.1. Product Type
  1.2.2. Application
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
  1.5.1. Purchased Database
  1.5.2. GVR’s Internal Database
  1.5.3. Secondary Sources
  1.5.4. Primary Research
1.6. Information Analysis
  1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
  1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

CHAPTER 3. GERMANY & NETHERLANDS MEDICAL MARIJUANA MARKET VARIABLES, TRENDS, & SCOPE

3.1. Market Lineage Outlook
3.2. Market Dynamics
  3.2.1. Market Driver Analysis
  3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
  3.3.1. Industry Analysis – Porter’s Five Forces Analysis
    3.3.1.1. Supplier Power
    3.3.1.2. Buyer Power
    3.3.1.3. Substitution Threat
    3.3.1.4. Threat of New Entrant
    3.3.1.5. Competitive Rivalry
  3.3.2. PESTLE Analysis

CHAPTER 4. GERMANY & NETHERLANDS MEDICAL MARIJUANA MARKET: PRODUCT TYPE BUSINESS ANALYSIS

4.1. Product Type Market Share, 2024 & 2030
4.2. Product Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product Type, 2018 to 2030 (USD Million)
4.4. Flower
  4.4.1. Flower Market, 2018 - 2030 (USD Million)
4.5. Oil
  4.5.1. Oil Market, 2018 - 2030 (USD Million)

CHAPTER 5. GERMANY & NETHERLANDS MEDICAL MARIJUANA MARKET: APPLICATION BUSINESS ANALYSIS

5.1. Application Market Share, 2024 & 2030
5.2. Application Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
5.4. Chronic Pain
  5.4.1. Chronic Pain Market, 2018 - 2030 (USD Million)
5.5. Mental Disorders
  5.5.1. Mental Disorders Market, 2018 - 2030 (USD Million)

CHAPTER 6. GERMANY & NETHERLANDS MEDICAL MARIJUANA MARKET: COUNTRY ESTIMATES & TREND ANALYSIS

6.1. Country Market Share Analysis, 2024 & 2030
6.2. Country Market Dashboard
6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.4. Germany
  6.4.1. Germany Medical Marijuana Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.4.2. Key Country Dynamics
  6.4.3. Regulatory Framework
  6.4.4. Competitive Insights
6.5. Netherlands
  6.5.1. Netherlands Medical Marijuana Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.5.2. Key Country Dynamics
  6.5.3. Regulatory Framework
  6.5.4. Competitive Insights

CHAPTER 7. COMPETITIVE LANDSCAPE

7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
  7.5.1. ADREXpharma GmbH
    7.5.1.1. Overview
    7.5.1.2. Financial Performance
    7.5.1.3. Product Type Benchmarking
    7.5.1.4. Strategic Initiatives
  7.5.2. Canopy Growth Corporation
    7.5.2.1. Overview
    7.5.2.2. Financial Performance
    7.5.2.3. Product Type Benchmarking
    7.5.2.4. Strategic Initiatives
  7.5.3. Aphria, Inc
    7.5.3.1. Overview
    7.5.3.2. Financial Performance
    7.5.3.3. Product Type Benchmarking
    7.5.3.4. Strategic Initiatives
  7.5.4. Aurora Cannabis
    7.5.4.1. Overview
    7.5.4.2. Financial Performance
    7.5.4.3. Product Type Benchmarking
    7.5.4.4. Strategic Initiatives
  7.5.5. Tilray
    7.5.5.1. Overview
    7.5.5.2. Financial Performance
    7.5.5.3. Product Type Benchmarking
    7.5.5.4. Strategic Initiatives
  7.5.6. GW Pharmaceuticals, plc
    7.5.6.1. Overview
    7.5.6.2. Financial Performance
    7.5.6.3. Product Type Benchmarking
    7.5.6.4. Strategic Initiatives
  7.5.7. Organigram Holdings, Inc.
    7.5.7.1. Overview
    7.5.7.2. Financial Performance
    7.5.7.3. Product Type Benchmarking
    7.5.7.4. Strategic Initiatives
  7.5.8. The Cronos Group
    7.5.8.1. Overview
    7.5.8.2. Financial Performance
    7.5.8.3. Product Type Benchmarking
    7.5.8.4. Strategic Initiatives
  7.5.9. Demecan GmbH
    7.5.9.1. Overview
    7.5.9.2. Financial Performance
    7.5.9.3. Product Type Benchmarking
    7.5.9.4. Strategic Initiatives
  7.5.10. Cannamedical Pharma GmbH
    7.5.10.1. Overview
    7.5.10.2. Financial Performance
    7.5.10.3. Product Type Benchmarking
    7.5.10.4. Strategic Initiatives